MX2009003257A - Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina. - Google Patents

Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.

Info

Publication number
MX2009003257A
MX2009003257A MX2009003257A MX2009003257A MX2009003257A MX 2009003257 A MX2009003257 A MX 2009003257A MX 2009003257 A MX2009003257 A MX 2009003257A MX 2009003257 A MX2009003257 A MX 2009003257A MX 2009003257 A MX2009003257 A MX 2009003257A
Authority
MX
Mexico
Prior art keywords
synthesis
diaminopyrimidine derivatives
phenoxy
phenoxy diaminopyrimidine
derivatives
Prior art date
Application number
MX2009003257A
Other languages
English (en)
Inventor
Charles Alois Dvorak
Keena Lynn Green
Gary R Lee
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009003257A publication Critical patent/MX2009003257A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Abstract

Se describe un método para preparar un compuesto de la fórmula k o una sal o solvato del mismo, en donde R1 es como se define en la presente, el método comprende tratar un compuesto de la fórmula j o una sal o solvato del mismo, con amoniaco, para formar el compuesto de la fórmula k.
MX2009003257A 2006-10-04 2007-09-24 Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina. MX2009003257A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84920306P 2006-10-04 2006-10-04
PCT/EP2007/060095 WO2008040652A1 (en) 2006-10-04 2007-09-24 Process for synthesis of phenoxy diaminopyrimidine derivatives

Publications (1)

Publication Number Publication Date
MX2009003257A true MX2009003257A (es) 2009-04-07

Family

ID=39004835

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003257A MX2009003257A (es) 2006-10-04 2007-09-24 Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.

Country Status (15)

Country Link
US (3) US8003788B2 (es)
EP (2) EP2079713B1 (es)
JP (2) JP5128603B2 (es)
KR (1) KR101176701B1 (es)
CN (2) CN102432548A (es)
AU (1) AU2007304280B2 (es)
BR (1) BRPI0719955B1 (es)
CA (1) CA2664305C (es)
DK (1) DK2343281T3 (es)
ES (2) ES2461595T3 (es)
IL (3) IL197639A (es)
MX (1) MX2009003257A (es)
PL (1) PL2343281T3 (es)
SI (1) SI2343281T1 (es)
WO (1) WO2008040652A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009003257A (es) * 2006-10-04 2009-04-07 Hoffmann La Roche Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.
MY195728A (en) 2013-08-23 2023-02-07 Afferent Pharmaceuticals Inc Diaminopyrimidine P2x3 and P2x 2/3 Receptor Modulators for Treatment of Acute, Sub-Acute or Chronic Cough
CN105085847B (zh) * 2014-05-23 2018-05-04 中国科学院宁波材料技术与工程研究所 一种磺酰胺化芳香族聚合物、其制备方法及应用
US10195198B2 (en) 2014-07-03 2019-02-05 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
HRP20230445T1 (hr) * 2015-09-29 2023-07-21 Afferent Pharmaceuticals Inc. Modulatori diaminopirimidin p2x3 i p2x2/3 receptora za primjenu u liječenju kašlja
BR112018069105A2 (pt) 2016-03-25 2019-01-29 Afferent Pharmaceuticals Inc pirimidinas e variantes das mesmas, e usos para tais
US10676444B2 (en) * 2016-12-20 2020-06-09 Afferent Pharmaceuticals, Inc. Crystalline salts and polymorphs of a P2X3 antagonist
AU2019257606A1 (en) * 2018-04-23 2020-10-01 Msd Werthenstein Biopharma Gmbh Novel process for synthesis of a phenoxy diaminopyrimidine compound
JP2022530890A (ja) 2019-04-30 2022-07-04 ベイジン タイド ファーマシューティカル カンパニー リミテッド ジアミノピリミジン化合物を使用することによって咳を治療する方法
CN111635368B (zh) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
US20230357163A1 (en) 2020-09-17 2023-11-09 Teva Pharmaceuticals International Gmbh Solid state forms of gefapixant and process for preparation thereof
CN113336680B (zh) * 2021-06-04 2023-10-03 寿光永康化学工业有限公司 一种磺胺的绿色工艺合成方法
CN113773300B (zh) * 2021-09-27 2022-10-11 成都施贝康生物医药科技有限公司 磺酰胺类化合物、其制备方法及用途
CN113801097B (zh) * 2021-09-27 2022-11-22 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物、其制备方法及用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763450A (en) * 1994-11-24 1998-06-09 Hoffmann-La Roche Inc. Substituted benzyl pyrimidines
AUPQ968700A0 (en) * 2000-08-28 2000-09-21 Intreat Pty Limited Treatment of urinary incontinence
EP1541575B1 (en) * 2002-07-29 2010-03-03 Sumitomo Chemical Company, Limited Novel process for producing imidazo(1,2-b)pyridazine derivative
CN1930135B (zh) * 2004-03-05 2011-12-28 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3拮抗剂的二氨基嘧啶
SE0401716D0 (sv) * 2004-07-02 2004-07-02 Astrazeneca Ab New compounds
US7544702B2 (en) * 2004-08-12 2009-06-09 Amgen Inc. Bisaryl-sulfonamides
JP4246207B2 (ja) * 2005-02-21 2009-04-02 住友化学株式会社 除草剤組成物
BRPI0615040A2 (pt) * 2005-09-01 2011-04-26 Hoffmann La Roche diaminopirimidinas como moduladores de p2x3 e p2x2/3
ATE529413T1 (de) * 2005-09-01 2011-11-15 Hoffmann La Roche Verfahren zur synthese von aryloxydiaminopyrimidinen
MX2009003257A (es) * 2006-10-04 2009-04-07 Hoffmann La Roche Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines

Also Published As

Publication number Publication date
US8003788B2 (en) 2011-08-23
EP2343281B1 (en) 2014-03-05
CA2664305C (en) 2016-06-07
KR20090055043A (ko) 2009-06-01
JP5669793B2 (ja) 2015-02-18
ES2461595T3 (es) 2014-05-20
AU2007304280B2 (en) 2013-01-31
US8580960B2 (en) 2013-11-12
SI2343281T1 (sl) 2014-06-30
AU2007304280A1 (en) 2008-04-10
IL197639A (en) 2015-02-26
EP2343281A1 (en) 2011-07-13
CN101522641B (zh) 2012-07-04
EP2079713B1 (en) 2014-04-16
IL197639A0 (en) 2009-12-24
EP2079713A1 (en) 2009-07-22
DK2343281T3 (en) 2014-03-24
BRPI0719955A2 (pt) 2014-04-29
CN102432548A (zh) 2012-05-02
CA2664305A1 (en) 2008-04-10
IL254426A0 (en) 2017-11-30
US20110269961A1 (en) 2011-11-03
KR101176701B1 (ko) 2012-08-23
JP2013010780A (ja) 2013-01-17
JP5128603B2 (ja) 2013-01-23
BRPI0719955B1 (pt) 2024-01-09
CN101522641A (zh) 2009-09-02
US9643934B2 (en) 2017-05-09
US20140045871A1 (en) 2014-02-13
WO2008040652A1 (en) 2008-04-10
IL234545A (en) 2017-10-31
JP2010505790A (ja) 2010-02-25
ES2466667T3 (es) 2014-06-10
PL2343281T3 (pl) 2014-08-29
US20080086004A1 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
MX2009003257A (es) Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.
MX337588B (es) Metodo para preparar derivados de 5-haloalquil-4,5-dihidroisoxasol .
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
MX2009005616A (es) Derivados de pirido-pirazina utiles como compuestos herbicidas.
AU2015221439B2 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
TW200720366A (en) Process for preparing metal compounds of an azo compound in the presence of seed crystals
MX2009003739A (es) Derivados de hidrobenzamida como inhibidores de hsp90.
IL178771A0 (en) 2-pyridinylcycloalkylcarboxamide derivatives useful as fungicides
NZ593874A (en) Nalmefene hydrochloride dihydrate
WO2009154754A3 (en) Synthesis of deuterated morpholine derivatives
MX2012013332A (es) Preparacion de intermediarios de posaconazol.
GEP20125512B (en) Process for synthesis of agomelatin
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
TW200612959A (en) Method for preparing hydroxamic acids
MXPA05013751A (es) Procedimiento e intermediarios para la preparacion de 3-(amino)-3-ciclobutilmetil-2-hidroxi-propionamida o sus sales.
IL185545A0 (en) Method of preparation of pure 4-pyrrolidinophenylbenzyl ether derivatives as maob inhibitors
TW201129550A (en) Method for producing diepoxy compound
MX2011011025A (es) Preparacion de c-piracin-metilaminas.
TW200738650A (en) Process for synthesis of aryloxy diaminopyrimidines
EA201001252A1 (ru) Способ получения производных 3,6-дигидро-1,3,5-триазина
TW201129575A (en) Metal complex having pyridylphosphine compound, and method for producing alkyl methacrylate
ZA200800138B (en) Process for the preparation of crystalline perindopril
WO2012015255A3 (en) Novel montelukast 4-halobenzylamine salt and method for preparing montelukast sodium salt by using the same
NZ589496A (en) Processes and compounds for the preparation of normorphinans
UA102091C2 (ru) Способ получения сульфонилпиролов как ингибиторов hdac

Legal Events

Date Code Title Description
FG Grant or registration